Analysis of Panitumumab Use in the Clinical Practice [artículo]
Por: Cortijo Cascajares, Susana [Farmacia]
| Amuriza Chicharro, Natalia de [Farmacia] | Herreros de Tejada López-Coterilla, Alberto [Farmacia] | Aguilella Vizcaíno, María José [Farmacia] | Goyache Goñi, María del Puy [Farmacia] | Gastalver Martín, Cristina [Farmacia].
Colaborador(es): Servicio de Farmacia Hospitalaria.
Editor: Atención Farmaceútica, 2012Descripción: 2012:14(4):270-5.Recursos en línea: Solicitar documento
En: Resumen: Objective: To understand panitumumab use and safety in the clinical practice. Method: We conducted a retrospective study in the years 2009 and 2010, which included all those patients who had received panitumumab during this period. The collected variables were age, prior treatments, number of cycles, dose, pattern, changes in dose and pattern, adverse effects and cause for treatment suspension. Results: We found that the majority of patients received panitumumab after other treatments failed. 48% of the population took panitumumab combined with other medications. The most common adverse reactions were dermatological. The adverse reaction profile did not vary in a significant way between the two types of administration. 13.4% of patients who received panitumumab were suffering from head and neck cancer Conclusions: We observed an extended use of panitumumab in a polytherapy regime. This last one was more effective than in monotherapy, with a slightly higher toxicity.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC3665 (Navegar estantería) | Disponible |
Formato Vancouver:
Gastalver Martín C, Cortijo Cascajares N, De Amuriza Chicharro N, Aguilella Vizcaíno MJ, Goyache-Goñi MP, Herreros de Tejada López Coterilla A. Análisis de utilización de Panitumumab en la práctica clínica. Aten Farm. 2012:14(4):270-5.
Objective: To understand panitumumab use and safety in the clinical practice. Method: We conducted a retrospective study in the years 2009 and 2010, which included all those patients who had received panitumumab during this period. The collected variables were age, prior treatments, number of cycles, dose, pattern, changes in dose and pattern, adverse effects and cause for treatment suspension. Results: We found that the majority of patients received panitumumab after other treatments failed. 48% of the population took panitumumab combined with other medications. The most common adverse reactions were dermatological. The adverse reaction profile did not vary in a significant way between the two types of administration. 13.4% of patients who received panitumumab were suffering from head and neck cancer Conclusions: We observed an extended use of panitumumab in a polytherapy regime. This last one was more effective than in monotherapy, with a slightly higher toxicity.
No hay comentarios para este ejemplar.